Get started
Author

Oona Delpuech

PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP
2005 · Thomas Porstmann, Beatrice Griffiths, et al. · Oncogene · 467
FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression
2011 · E C Ferber, B Peck, et al. · Cell Death and Differentiation · 320
PDF
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
2018 · Chrysiis Michaloglou, Claire Crafter, et al. · Molecular Cancer Therapeutics · 184
Induction of Mxi1-SRα by FOXO3a Contributes to Repression of Myc-Dependent Gene Expression
2007 · Oona Delpuech, Beatrice Griffiths, et al. · Molecular and Cellular Biology · 164
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
2015 · Sylvie M. Guichard, Jon Curwen, et al. · Molecular Cancer Therapeutics · 134
PDF
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
2020 · James S. Scott, Thomas A. Moss, et al. · Journal of Medicinal Chemistry · 131
Involvement of MINK, a Ste20 Family Kinase, in Ras Oncogene-Induced Growth Arrest in Human Ovarian Surface Epithelial Cells
2005 · Barbara Nicke, Julie Bastien, et al. · Molecular Cell · 110
PDF
Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma
2002 · Oona Delpuech, Jean-Baptiste Trabut, et al. · Oncogene · 95
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
2023 · Mandy Lawson, Natalie Cureton, et al. · Cancer Research · 83
PDF
Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection
2003 · Massimo Iavarone, Jean-Baptiste Trabut, et al. · Journal of Hepatology · 79
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
2018 · Agostina Nardone, Hazel Weir, et al. · British Journal of Cancer · 70
PDF
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
2022 · Anna D. Staniszewska, Joshua Armenia, et al. · OncoImmunology · 62
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
2022 · Steven W. Criscione, Matthew J. Martin, et al. · npj Precision Oncology · 59
PDF
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
2018 · Sophie Langdon, Adina Hughes, et al. · OncoImmunology · 53
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
2021 · Claudia Winkler, Matthew King, et al. · JCI Insight · 44
PDF
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers
2016 · James R. Bradford, Mark Wappett, et al. · Oncotarget · 41
PDF
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers
2016 · Kevin Hudson, Urs J. Hancox, et al. · Molecular Cancer Therapeutics · 41
PDF
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
2017 · James T. Lynch, Urszula M. Polanska, et al. · Clinical Cancer Research · 35
Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC
2016 · M A Taylor, M Wappett, et al. · Oncogene · 33
PDF
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib
2013 · James R. Bradford, Matthew Farren, et al. · PLoS ONE · 33
PDF
Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells
2017 · A G Trinidad, N Whalley, et al. · Oncogene · 31
PDF
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
2018 · James T. Lynch, Urszula M. Polanska, et al. · Molecular Cancer Therapeutics · 29
Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
2016 · Oona Delpuech, Claire Rooney, et al. · Molecular Cancer Therapeutics · 28
PDF
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
2019 · Liliana D. Ordonez, Trevor Hay, et al. · Oncotarget · 26
PDF
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
2020 · Vikki Flemington, Emma J. Davies, et al. · Molecular Cancer Therapeutics · 24
Works count: 147
Citation count: 2,476
H-index: 24
I10-index: 30
Year
Topic
Type